Lei Zhang

Dr. Lei Zhang


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2019 in Molecular Reproduction and Development
Verified
Journal Article
Closed access
PDF file
HCHuanhuan Chen
Huanhuan Chen
LZLei Zhang
Lei Zhang
ZWZhenqiang Wang
Zhenqiang Wang
HCHaoya Chang
Haoya Chang
XXXiaogang Xie
Xiaogang Xie
FQFusheng Quan
Fusheng Quan

13 August 2019 in Molecular Reproduction and Development
Verified
Journal Article
Closed access
PDF file
HCHaoya Chang
Haoya Chang
HCHuanhuan Chen
Huanhuan Chen
LZLei Zhang
Lei Zhang
YWYile Wang
Yile Wang
XXXiaogang Xie
Xiaogang Xie
FQFusheng Quan
Fusheng Quan

1 April 2016 in Neurology Genetics
Verified
Journal Article
Open access
PDF file
Yi YangYi Yang
Yi Yang
LZLei Zhang
Lei Zhang
DLDavid R. Lynch
David R. Lynch
TLThomas Lukas
Thomas Lukas
KAKreshnik Ahmeti
Kreshnik Ahmeti
TSTeepu Siddique
Teepu Siddique
Objective: To identify the genetic defect for adult-onset primary lateral sclerosis (PLS) in a family with 5 patients. Methods: Whole-exome sequencing was performed to identify the shared genetic variants in 3 affected members in a PLS family with 5 affected individuals. Sanger sequencing was used for validation of the variants and for cosegregation analysis. Mitochondrial activity for both patients and unaffected siblings was measured using a SeaHorse metabolic analyzer. Results: Whole-exome sequencing and subsequent cosegregation analysis demonstrated that compound heterozygous missense variants L695P and I743T in SPG7 were the only mutations cosegregating with the disease in an autosomal recessive fashion in this family. The parents and siblings are genetically heterozygous and clinically unaffected. Functional studies suggested that the PLS-associated SPG7 mutants affect mitochondrial function when glucose is reduced. Conclusions: Compound heterozygote mutations in SPG7 are associated with adult-onset PLS, extending the spectrum of SPG7-linked neurologic diseases. Patients with the PLS phenotype should have genetic testing for paraplegin, especially when the condition is familial.

12 January 2022 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
KFKe Feng
Ke Feng
HGHengtao Ge
Hengtao Ge
HCHuanhuan Chen
Huanhuan Chen
CCChenchen Cui
Chenchen Cui
SZShan Zhang
Shan Zhang
LZLei Zhang
Lei Zhang
Non‐obstructive azoospermia (NOA) is a common cause of male infertility, and genetic problems, such as chromosomal abnormalities and gene mutations, are important causes of NOA. Our centre received a case of NOA, in which no mature sperm was found during microdissection testicular sperm extraction. A postoperative pathological examination revealed that testicular spermatogenesis was blocked. Target region capture combined with high‐throughput sequencing was used to screen for male infertility‐related gene mutations. Sanger sequencing further confirmed that the SYCE1 gene, a central component of the synaptonemal complex (SC) during meiosis, had a homozygous deletion mutation in the tenth exon (c.689_690del; p.F230fs). Through molecular biological studies, we discovered altered expression and nuclear localization of the endogenous mutant SYCE1. To verify the effects in vitro, wild‐ and mutated‐type SYCE1 vectors were constructed and transfected into a human cell line. The results showed that the expression and molecular weight were decreased for SYCE1 containing c.689_690del. In addition, mutated SYCE1 was abnormally located in the cytoplasm rather than in the nucleus. In summary, our research suggests that the novel homozygous mutation (c.689_690del; p.F230fs) altered the SYCE1 expression pattern and may have disturbed SC assembly, leading to male infertility and to a barrier to gamete formation. We reported for the first time that a frameshift mutation occurred in the exon region of SYCE1 in an NOA patient. This study is beneficial for accurate NOA diagnosis and the development of corresponding gene therapy strategies.

1 May 2015 in Forensic Science International: Genetics
Verified
Journal Article
Closed access
YLYu Xuan Liu
Yu Xuan Liu
WZWen Qiong Zhang
Wen Qiong Zhang
YJYun Jia
Yun Jia
LZLei Zhang
Lei Zhang
FZFeng Lei Zhou
Feng Lei Zhou
SYShao Hua Yi
Shao Hua Yi

Verified
Journal Article
Open access
PDF file
XWXing Wei
Xing Wei
LYLiu Yingxiang
Liu Yingxiang
WHWeijie Hao
Weijie Hao
PFPeiwen Feng
Peiwen Feng
LZLei Zhang
Lei Zhang
ZGZekun Guo
Zekun Guo
DNA methylation is an epigenetic modification that plays a vital role in a variety of biological processes, including the regulation of gene expression, cell differentiation, early embryonic development, genomic imprinting, and X chromosome inactivation. PGC7 is a maternal factor that maintains DNA methylation during early embryonic development. One mechanism of action has been identified by analyzing the interactions between PGC7 and UHRF1, H3K9 me2, or TET2/TET3, which reveals how PGC7 regulates DNA methylation in oocytes or fertilized embryos. However, the mechanism by which PGC7 regulates the post-translational modification of methylation-related enzymes remains to be elucidated. This study focused on F9 cells (embryonic cancer cells), which display high levels of PGC7 expression. We found that both knockdown of Pgc7 and inhibition of ERK activity resulted in increased genome-wide DNA methylation levels. Mechanistic experiments confirmed that inhibition of ERK activity led to the accumulation of DNMT1 in the nucleus, ERK phosphorylated DNMT1 at ser717, and DNMT1 Ser717-Ala mutation promoted the nuclear localization of DNMT1. Moreover, knockdown of Pgc7 also caused downregulation of ERK phosphorylation and promoted the accumulation of DNMT1 in the nucleus. In conclusion, we reveal a new mechanism by which PGC7 regulates genome-wide DNA methylation via phosphorylation of DNMT1 at ser717 by ERK. These findings may provide new insights into treatments for DNA methylation-related diseases.